| Patient | James Madison |
|---|---|
| Date of birth | 2003-03-16 |
| Identifiers | MRN HR-EN007-SYN; SSN (made up) 000-07-2618 |
| Document date | 2026-11-01 |
| Author | Josiah Pembroke-Achebe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for two years of recurrent sudden episodes of unresponsiveness, with low mood and anxiety, on levetiracetam started without a diagnosis. Concerns: For two years he has had sudden spells in which his mind seems to stop; he is afraid of having one in public or at the wheel; He feels low and worried, and does not expect to live long; He wants to know whether he has epilepsy and whether he can study law and take part in public life. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Levetiracetam 500 mg oral tablet, one tablet twice daily, started at an emergency department visit four months before intake for possible seizures, without an EEG | One tablet twice daily | Oral route | 2025-12-02 to 2026-04-30 | completed | S |
| Levetiracetam 500 mg oral tablet, taper: half a tablet (250 mg) twice daily for two weeks, then half a tablet at night for one week, then stop | Half a tablet twice daily for two weeks, then half a tablet at night for one week, then stop | Oral route | 2026-04-30 to 2026-05-21 | completed | S |
| Sertraline 50 mg oral tablet, half a tablet (25 mg) each morning for one week, then one tablet (50 mg) each morning | Half a tablet each morning for one week, then one tablet each morning | Oral route | 2026-06-11 | active | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for vomiting, for up to three days | One tablet every 8 hours as needed for vomiting, up to three days | Oral route | 2026-08-20 to 2026-08-23 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Resting 12-lead ECG: sinus rhythm at 76 per minute; normal PR, QRS, and QTc (404 ms); no pre-excitation, Brugada pattern, or heart block | 2026-04-07 to 2026-04-07 | completed | S |
| MRI of the brain with an epilepsy protocol (3 tesla, thin coronal sections through the hippocampi): normal; no hippocampal sclerosis, cortical malformation, or other lesion | 2026-04-14 to 2026-04-14 | completed | S |
| Inpatient video-EEG monitoring for 72 hours with sleep deprivation, hyperventilation, and photic stimulation, levetiracetam continued: two habitual events captured (2 minutes 40 seconds and 6 minutes), each with eyes closed and resisting opening, fluctuating unresponsiveness, and slow side-to-side head movements, during which the EEG showed a continuous normal waking posterior rhythm with no ictal or postictal change; normal interictal EEG awake and asleep; he confirmed both events as typical | 2026-04-27 to 2026-04-30 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2015-03-20 | Tdap vaccine, adolescent dose | completed | S |
| 2015-09-18 | HPV vaccine, 9-valent, two-dose series completed | completed | S |
| 2026-07-16 | Tdap vaccine, adult booster | completed | S |
| 2026-09-24 | Influenza vaccine, 2026-2027 season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| Childhood | A frail and sickly child, by the Library of Congress's account | D (CLM-0003) |
| 1771 to 1772 | Infirm health at college, which he put down to doing two years' work in one; for months he slept only three hours a night | D (CLM-0004) |
| November 1772 | Wrote that he felt dull and infirm and did not expect a long or healthy life | D (CLM-0005) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| For two years he has had sudden spells in which his mind seems to stop; he is afraid of having one in public or at the wheel | active | S |
| He feels low and worried, and does not expect to live long | active | S |
| He wants to know whether he has epilepsy and whether he can study law and take part in public life | active | S |
Most recent measures: Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 2026-09-24; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 7 on 2026-09-24; Total score [AUDIT-C] 1 on 2026-07-16; Hemoglobin [Mass/volume] in Blood 14.9 on 2026-04-07; Leukocytes [#/volume] in Blood by Automated count 6.4 on 2026-04-07; Platelets [#/volume] in Blood by Automated count 231 on 2026-04-07; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-04-07; Potassium [Moles/volume] in Serum or Plasma 4.2 on 2026-04-07; Creatinine [Mass/volume] in Serum or Plasma 0.86 on 2026-04-07; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 125 on 2026-04-07; Glucose [Mass/volume] in Serum or Plasma 84 on 2026-04-07; Calcium [Mass/volume] in Serum or Plasma 9.6 on 2026-04-07; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 2026-04-07; Q-T interval corrected 404 on 2026-04-07 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent sudden episodes of unresponsiveness for two years, two or three a month: he 'blanks out', stops speaking, slumps or sinks to the floor with his eyes closed for two to ten minutes, and afterwards is tearful and tired, with no tongue biting, incontinence, or injury; first during a period of overwork and little sleep at college; with low mood and anxiety; unchanged on levetiracetam; under evaluation for epilepsy, functional (dissociative) seizures, syncope, and other causes | resolved | confirmed | R40.4 | S — Synthetic presenting problem echoing his documented overwork, infirm health, and low spirits, and the later accounts of sudden attacks; superseded by the diagnosis at the second visit. |
| Taking an antiseizure medicine (levetiracetam) started without a confirmed diagnosis of epilepsy | resolved | confirmed | Z79.899 | S — Synthetic medication problem for teaching about avoiding unneeded antiseizure medicines; resolved when the medicine was stopped. |
| Functional/dissociative seizures (psychogenic nonepileptic seizures), documented by video-EEG: two habitual events captured with eyes closed and resisting opening, fluctuating unresponsiveness, and a normal waking EEG throughout, with no ictal or postictal change; normal interictal EEG and brain MRI; epilepsy and syncope excluded | active | confirmed | F44.5 | S — Synthetic modern diagnosis. His infirm health, overwork, and low spirits in youth are documented (D); retrospective explanations of his later attacks, including epilepsy, are disputed (R). This record does not assert what his attacks were. |
| Generalized anxiety disorder: worry about his future, his health, and his studies most days for more than a year, with restlessness, poor sleep, and muscle tension (GAD-7 14 at intake) | active | confirmed | F41.1 | S — Synthetic diagnosis made at the neuropsychiatric assessment during video-EEG monitoring. |
| Major depressive disorder, single episode, moderate: low mood, loss of interest, poor sleep and concentration, and a sense that he will not live long, for about eighteen months (PHQ-9 13 at intake); no suicidal ideation or intent | active | confirmed | F32.1 | S — Synthetic diagnosis echoing, without asserting, his documented letter expecting an early death. |
| Acute viral gastroenteritis with mild dehydration, a day of vomiting and diarrhea after a household outbreak; one functional seizure the evening before the visit; resolved | resolved | confirmed | A08.4 | S — Synthetic intercurrent illness at an unscheduled visit; it echoes, without asserting, the 'bilious' illnesses recorded in his later life (CLM-0010). |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-07 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 13 | {score} | S | ||
| 2026-04-07 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 14 | {score} | S | ||
| 2026-04-07 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 2026-04-07 | Hemoglobin [Mass/volume] in Blood | 14.9 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-04-07 | Leukocytes [#/volume] in Blood by Automated count | 6.4 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 2026-04-07 | Platelets [#/volume] in Blood by Automated count | 231 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-07 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-07 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-07 | Creatinine [Mass/volume] in Serum or Plasma | 0.86 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-07 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 125 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-07 | Glucose [Mass/volume] in Serum or Plasma | 84 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-07 | Calcium [Mass/volume] in Serum or Plasma | 9.6 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-04-07 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 2026-04-07 | Q-T interval corrected | 404 | ms | Below 450 ms is normal for a man | Normal | S |
| 2026-04-30 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 12 | {score} | S | ||
| 2026-04-30 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 13 | {score} | S | ||
| 2026-06-11 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 11 | {score} | S | ||
| 2026-06-11 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 12 | {score} | S | ||
| 2026-07-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-07-16 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 2026-09-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-09-24 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-07 | Body height | 168 | cm | S |
| 2026-04-07 | Body weight | 54 | kg | S |
| 2026-04-07 | Body mass index (BMI) [Ratio] | 19.1 | kg/m2 | S |
| 2026-04-07 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-04-07 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-04-07 | Heart rate | 76 | /min | S |
| 2026-04-07 | Respiratory rate | 14 | /min | S |
| 2026-04-07 | Body temperature | 36.7 | Cel | S |
| 2026-04-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-04-30 | Body height | 168 | cm | S |
| 2026-04-30 | Body weight | 54.2 | kg | S |
| 2026-04-30 | Body mass index (BMI) [Ratio] | 19.2 | kg/m2 | S |
| 2026-04-30 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-04-30 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-04-30 | Heart rate | 72 | /min | S |
| 2026-04-30 | Respiratory rate | 14 | /min | S |
| 2026-04-30 | Body temperature | 36.6 | Cel | S |
| 2026-04-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-06-11 | Body height | 168 | cm | S |
| 2026-06-11 | Body weight | 54.6 | kg | S |
| 2026-06-11 | Body mass index (BMI) [Ratio] | 19.3 | kg/m2 | S |
| 2026-06-11 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-06-11 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-06-11 | Heart rate | 74 | /min | S |
| 2026-06-11 | Respiratory rate | 14 | /min | S |
| 2026-06-11 | Body temperature | 36.6 | Cel | S |
| 2026-06-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-07-16 | Body height | 168 | cm | S |
| 2026-07-16 | Body weight | 55 | kg | S |
| 2026-07-16 | Body mass index (BMI) [Ratio] | 19.5 | kg/m2 | S |
| 2026-07-16 | Systolic blood pressure | 114 | mm[Hg] | S |
| 2026-07-16 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-07-16 | Heart rate | 70 | /min | S |
| 2026-07-16 | Respiratory rate | 14 | /min | S |
| 2026-07-16 | Body temperature | 36.6 | Cel | S |
| 2026-07-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-08-20 | Body height | 168 | cm | S |
| 2026-08-20 | Body weight | 53.6 | kg | S |
| 2026-08-20 | Body mass index (BMI) [Ratio] | 19 | kg/m2 | S |
| 2026-08-20 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-08-20 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-08-20 | Heart rate | 102 | /min | S |
| 2026-08-20 | Respiratory rate | 16 | /min | S |
| 2026-08-20 | Body temperature | 37.7 | Cel | S |
| 2026-08-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-09-24 | Body height | 168 | cm | S |
| 2026-09-24 | Body weight | 55.2 | kg | S |
| 2026-09-24 | Body mass index (BMI) [Ratio] | 19.6 | kg/m2 | S |
| 2026-09-24 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-09-24 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-09-24 | Heart rate | 68 | /min | S |
| 2026-09-24 | Respiratory rate | 14 | /min | S |
| 2026-09-24 | Body temperature | 36.6 | Cel | S |
| 2026-09-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-04-07 | Primary care visit for two years of recurrent sudden episodes of unresponsiveness, with low mood and anxiety, on levetiracetam started without a diagnosis | finished | S |
| 2026-04-30 | Discharge-day review after video-EEG monitoring: diagnosis, its explanation, and the epilepsy and functional neurological disorder consultation | finished | S |
| 2026-06-11 | Six-week review after the diagnosis: levetiracetam withdrawn, psychotherapy under way, mood and anxiety | finished | S |
| 2026-09-24 | Three-month review after completing psychotherapy: events, mood, driving, and his studies | finished | S |
| 2026-07-16 | Preventive health visit at 23 | finished | S |
| 2026-08-20 | Same-day sick visit for viral gastroenteritis | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Diagnostic workup: a detailed history including a witness account or phone video if available, ECG, blood count, metabolic panel, TSH, brain MRI with an epilepsy protocol, and inpatient video-EEG monitoring to capture his habitual events; levetiracetam continued unchanged until the evaluation is complete | completed | GL-ILAE-PNES-2013, GL-ILAE-FDS-2025, GL-ILAE-SZ-2017, GL-ILAE-DEF-2014 | S |
| Safety now: no driving until the evaluation is complete and the neurologist advises; showers rather than baths, no swimming alone or working at heights; seizure first aid for the people he lives and works near | completed | GL-AAN-DRIVE-2025, GL-CDC-SZFIRSTAID | S |
| Suicide risk assessment with a written safety plan: warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; the rifle locked with the ammunition stored separately; safety reviewed at every visit | completed | GL-SUICIDE-2024, GL-CMID-2026 | S |
| Neurology consultation (epilepsy and functional neurological disorder) with admission for video-EEG monitoring, on the diagnosis, the antiseizure medicine, and treatment | completed | GL-ILAE-PNES-2013, GL-ILAE-FDS-2025, GL-ILAE-SZ-2017 | S |
| Explaining the diagnosis: functional/dissociative seizures named and explained in person and in writing as real, common, and not epilepsy or feigning; how the brain can switch off awareness under strain; why antiseizure medicines do not help; that treatment works; a reliable written and online resource; a follow-up appointment to answer questions | completed | GL-HALLPATCH-2010, GL-STONE-2016, GL-ILAE-FDS-2025 | S |
| Levetiracetam withdrawn: 250 mg twice daily for two weeks, 250 mg at night for one week, then stopped; no driving during the taper | completed | GL-ILAE-PNES-2013, GL-ILAE-FDS-2025, GL-ILAE-SZ-2017, GL-AAN-DRIVE-2025 | S |
| CBT-informed psychotherapy for functional seizures: twelve weekly sessions with a psychologist experienced in functional neurological disorder, with an event diary, recognition of warning sensations, grounding techniques, work on avoidance, sleep, and worry, and a relapse-prevention plan | completed | GL-LAFRANCE-2014, GL-CODES-2020, GL-ILAE-PNES-2013, GL-ILAE-FDS-2025, GL-ILAE-SZ-2017 | S |
| Measurement-based care for depression and anxiety: PHQ-9 and GAD-7 at least monthly during treatment; psychotherapy, an SSRI such as sertraline, or both, by shared decision once the cause of the events is clear | completed | GL-CMID-2026, GL-MDD-2022 | S |
| Studies and daily life: a regular sleep window of at least seven hours, study blocks with breaks, academic accommodations for testing (extra breaks), and a return to civic meetings with a friend who knows the first-aid plan | completed | GL-ILAE-PNES-2013, GL-ILAE-FDS-2025, GL-ILAE-SZ-2017, GL-LAFRANCE-2014, GL-CODES-2020 | S |
| Driving: may resume once free of events for at least three months and with the neurologist's agreement, following state licensing rules and the AAN 2025 position | completed | GL-AAN-DRIVE-2025 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Cause of the episodes established by the second visit | 2026-04-30 | completed | Functional/dissociative seizures documented by video-EEG; epilepsy and syncope excluded | S |
| Antiseizure medicine stopped safely | 2026-06-11 | completed | Levetiracetam tapered over three weeks and stopped, with no change in events and less irritability | S |
| Events reduced by at least half, then free of events for three months | 2026-12-31 | active | From two or three a month to one in the last two months; none for five weeks | S |
| Depression and anxiety improved by at least 50 percent (PHQ-9 and GAD-7) | 2026-12-31 | active | PHQ-9 13 to 6 and GAD-7 14 to 7 | S |
| No suicidal thoughts | 2026-12-31 | active | None at any visit | S |
Structured synthetic safety assessment on 2026-04-07: current ideation absent, intent absent, plan absent. No suicidal ideation, intent, plan, or behavior (C-SSRS screen negative; PHQ-9 item 9 scored 0); a fatalistic sense that he will not live long, without any wish to die. Moderate depression and anxiety with recurrent events raise risk, so: outpatient care with a written safety plan, the 988 Suicide & Crisis Lifeline and the clinic number, the rifle locked and the ammunition stored separately, and safety review at every visit [S]